Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
04. Februar 2020 08:30 ET
|
Celsion CORP
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) --...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
05. August 2019 09:00 ET
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...